Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bms-833923. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.48 |
| ▸ | TCF7L2 | Q9NQB0 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-833923 SCHEMBL29493087 | 1.00 | BACE1 (0.49) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL26460021 | 0.96 | KDM4E (0.47) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL26460135 | 0.94 | BACE1 (0.52) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL4142400 | 0.92 | CTNNB1 (0.47) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL4141957 | 0.91 | BACE1 (0.46) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL4135909 | 0.91 | BACE1 (0.49) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL4138339 | 0.91 | BACE1 (0.46) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL4138215 | 0.91 | BACE1 (0.46) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL4129985 | 0.91 | BACE1 (0.46) | BACE1CTNNB1TCF7L2MAPTTHRB | |
| SCHEMBL4139049 | 0.90 | PDGFRA (0.49) | BACE1CTNNB1TCF7L2MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108503-A1 | POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441 | UNIV DE GENE DE GENEVE (CH) | 2026-04-23 | — | — | US | claimed |
| CN-119997932-A | Polymeric micelle nanocarriers for targeted epidermal delivery of hedgehog pathway inhibitor TAK-441 | 日内瓦大学 | 2025-05-13 | — | — | CN | claimed |
| CN-118203665-A | Method for producing inner ear hair cells | 澳大利亚耳科学研究所股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| EP-3372673-B1 | METHOD FOR PRODUCING CEREBELLAR PROGENITOR TISSUE | RIKEN (JP) | 2023-12-13 | — | — | EP | claimed |
| US-20230364153-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | Research & Business Foundation Sungkyunkwan University (KR) | 2023-11-16 | — | — | US | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
| WO-2016042114-A1 | CXCL14 AS A BIOMARKER OF HEDGEHOG PATHWAY ACTIVITY FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-24 | — | — | WO | claimed |
| WO-2015073524-A1 | NOVEL METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE | DREXEL UNIVERSITY (US) | 2015-05-21 | — | — | WO | claimed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | claimed |
| CN-101679308-B | Inhibitors of the hedgehog pathway | EXELIXIS INC | 2014-05-07 | — | — | CN | claimed |
| US-20120245139-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-27 | — | — | US | claimed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | claimed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | claimed |
| US-20260108503-A1 | POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441 | UNIV DE GENE DE GENEVE (CH) | 2026-04-23 | — | — | US | disclosed |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | SECURA BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | BACE1 2093/4885CTNNB1 81/4885TCF7L2 36/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | BACE1 569/4885CTNNB1 256/4885TCF7L2 1178/4885 |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3R5, PIK3R4, PIK3CD | BACE1 4401/4885CTNNB1 1233/4885TCF7L2 2021/4885 |
| US-20120245139-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | BACE1 1857/4885CTNNB1 91/4885TCF7L2 42/4885 |
| US-20260108503-A1 | POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441 | SHH, SMO, GLI1 | BACE1 447/4885CTNNB1 24/4885TCF7L2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.